Objective-The role of cyclophilins (chaperones that are widely expressed in different cell types, including human platelets) was explored in sarcoendoplasmic calcium (Ca 2ϩ ) adenosine triphosphatase (SERCA) activity. Methods and Results-Cyclophilin inhibition by cyclosporin A (CsA) evoked a time-and concentration-dependent reduction of Ca 2ϩ uptake by SERCA2b. However, other Ca 2ϩ -adenosine triphosphatases expressed in platelets, such as SERCA3 and plasma membrane Ca 2ϩ adenosine triphophatase, remained unaltered after CsA treatment. Cypermethrin, a non-CsA-related calcineurin inhibitor, did not alter SERCA2b activity. Furthermore, SERCA2b was affected by other CsA analogues, which do not interfere with calcineurin, such as PKF-211-811-NX5 (NIM811) and sanglifehrin A. Inhibition of the immunophilin family members using FK506 (tacrolimus) did not alter SERCA2b ability to sequester Ca 2ϩ into the dense tubular system. Coimmunoprecipitation experiments confirmed that cyclophilin A associates with SERCA2b and stromal interaction molecule-1 in resting platelets. This interaction is attenuated by the physiological agonist thrombin but enhanced by treatment with CsA or sanglifehrin A. 
T he immunophilin family groups proteins with rotenase or peptidylprolyl cis-transisomerase activity. 1,2 These proteins have been classified according to their sensitivity to specific immunosuppressor drugs: cyclophilins (CyPs) are specific targets of cyclosporin A (CsA) [1] [2] [3] [4] ; immunophilins (FKBPs) are sensitive to FK506 (tacrolimus) and rapamycin (sirolimus), both structurally unrelated to CsA 4 -6 ; and FCBPs are sensitive to CsA and FK506. 2 CyPs are involved in two major cellular events: (1) indirect and nonspecific regulation of serine-threonine kinase proteins, an event mediated by the formation of stable CyP/CsA complexes that interact with the regulatory center of calcineurin (CaN), PP2B, or calcium (Ca 2ϩ )/calmodulin kinase (Ca 2ϩ /CaMK) phosphatase, reducing its activity 7 ; and (2) control of cell death by apoptosis through CyP D, which participates in the formation of the mitochondrial permeability transition pore and cytochrome c release in apoptotic cells. Furthermore, CyP B suppresses apoptosis evoked by oxidative, and endoplasmic reticulum, stress. 8 -10 Immunophilins participate in Ca 2ϩ homeostasis in several cell models. However, this role has been mainly attributed to FKBPs that control the opening of Ca 2ϩ channels located in the endoplasmic reticulum, such as ryanodine or inositol 1,4,5-trisphosphate receptors. [11] [12] [13] [14] In contrast, little is known about the role of immunophilins on Ca 2ϩ reuptake or extrusion mechanisms, and the current studies [13] [14] [15] [16] have reported contradictory results about the role of CyPs on the activity of sarcoendoplasmic Ca 2ϩ adenosine triphosphatase (ATPase) (SERCA) or the plasma membrane Ca 2ϩ ATPase (PMCA). In the present study, we have investigated the role of CyPs in the regulation of Ca 2ϩ reuptake by SERCA. We found that CsA reduces Ca 2ϩ reuptake by SERCA2b in a concentration-and time-dependent manner, without having any effect on SERCA3 or the PMCA activities. Regulation of SERCA2b activity was specific for CyPs and does not involve immunophilins or calcineurin, with an important role of CyP A, which might regulate SERCA2b through protein-protein interaction.
Methods
Platelets obtained from human healthy donors, according to the Declaration of Helsinki and local ethics committee guidelines, were isolated using the methods published elsewhere. 18 -20 Cytosolic Ca 2ϩ concentration [Ca 2ϩ ] c mobilization was determined in human platelets loaded with the fluorescent dye fura-2 using a spectrofluorophotometer. Alternatively, platelets were electroporated and incubated with anti-SERCA3 antibody, loaded with fura-2; [Ca 2ϩ ] c mobilization was determined as previously described. For the analysis of protein-protein interaction, platelet samples were subjected to immunoprecipitation and Western blotting, as described elsewhere. 9, 10 Detailed information about the materials and methods used can be found as supplementary data, available at http://atvb.ahajournals.org.
Results

CsA Increases Thrombin-Evoked Ca 2؉ Mobilization
In a Ca 2ϩ -free medium (100 mol/L of ethylene glycol tetraacetic acid [EGTA] was added), treatment of platelets with thrombin (Thr; 0.1 U/mL) evokes a rapid and transient increase in [Ca 2ϩ ] c as the result of Ca 2ϩ release from the intracellular stores, the dense tubular system, and the acidic stores, 18 followed by a Ca 2ϩ clearance through Ca 2ϩ -ATPases. As shown in Figure 1 , Ca 2ϩ mobilization evoked by Thr was significantly increased by 22.7Ϯ12.6% (meanϮSEM) after incubation for 5 minutes at 37°C with 50 mol/L of CsA (Figure 1 , inset; PϽ0.05; nϭ5).
CsA Reduces Ca 2؉ Reuptake by SERCA2b in Human Platelets
Consistent with previous studies, 18 -21 21 : SERCA2b, located in the dense tubular system; and SERCA3, located in the acidic organelles. 18, 19 Both SERCAs can be specifically inhibited by using either a low concentration of thapsigargin (TG) or 2,5-di-(tert-butyl)-1,4-hydroquinone (TBHQ), respectively. 20 -21 To investigate the effect of CsA on SERCA2b, we treated the cells with Thr, 0.1 U/mL, in combination with TBHQ, 20 mol/L. 18 -21 As shown in Figure 2A , Thr plus TBHQ evoked a peak in [Ca 2ϩ ] c that was similar in the absence and presence of CsA. However, These results were confirmed by electrotransjection of a specific anti-SERCA3 (PL/IM430) antibody, which has been reported to block Ca 2ϩ uptake by SERCA3. 22 As a control, we electrotransjected a mouse IgG of the same nature as the anti-SERCA3 antibody. In platelets electrotransjected with anti-SERCA3 antibody, Thr-evoked Ca 2ϩ elevation was reduced by 30.9Ϯ4.8% compared with control (IgG electrotransjected; PϽ0.01; nϭ4), which is a consequence of inhibition of SERCA3 and the subsequent attenuation of Ca 2ϩ reuptake. In the presence of anti-SERCA3 antibody, treatment with CsA significantly enhanced Thr-induced Ca 2ϩ release ( Figure 2D , PϽ0.05, nϭ6), which is consistent with the results using TBHQ (Figure 2A ).
CsA Does Not Modify SERCA3 Activity
We have further analyzed whether CsA alters SERCA3 activity by testing the effect of this inhibitor on Ca 2ϩ mobilization by Thr in combination with a low concentration, 10 nmol/L, of TG, which has been reported to selectively inhibit SERCA2b. 19, 20 As shown in Figure 3 , we did not observe any significant differences in Thr plus TG-evoked Ca 2ϩ mobilization, poststimulus [Ca 2ϩ ] c , or the amount of Ca 2ϩ remaining in the stores in the absence or presence of 50 mol/L of CsA. Taken together, these results indicate that CsA interferes with SERCA2b, but not with SERCA3.
CsA Does Not Modify PMCA Activity
In addition, we tested the possible effects of CsA on PMCA. As shown in Supplemental Figure I (online Data Supplement; http://atvb.ahajournals.org), treatment of human platelets in a Ca 2ϩ -free medium with 50 mol/L of CsA for 5 minutes did not modify the rate of decay of [Ca 2ϩ ] c to basal levels after treatment with TG, 200 nmol/L, plus Iono, 100 nmol/L, which has been used as an indicator for PMCA activity in platelets; Ca 2ϩ extrusion by the sodium/Ca 2ϩ exchanger has a minor role in the range of concentrations reached in our experimental conditions. 23 The decay constants in the presence and absence of CsA were 0.05288Ϯ0.00720 and 0.05132Ϯ0.00350, respectively (Pϭ0.82; nϭ6).
Effect of CsA on Calcium Homeostasis Is Independent of the Mitochondrial Uncoupling
To investigate a possible role of mitochondria on CsAmediated effects on Ca 2ϩ mobilization, 8,9,24,25 we repeated some experiments in the presence of the mitochondrial 
SERCA2b Activity Is Independent of Immunophilins
We further tested whether immunophilins or FKBPs also participate in the inhibition of SERCA2b activity previously reported. To investigate this issue, we incubated human platelets for 5 minutes at 37°C with 10 and 50 mol/L of FK506. As shown in Figure 4 , FK506 slightly increased the Ca 2ϩ mobilization induced by Thr, 0.1 U/mL, plus THBQ, 20 mol/L, by 6% and 8% at 10 and 50 mol/L, respectively (nϭ4 -6). We did not detect any significant effect of FK506 on the rate of decay of [ 
Reduction of SERCA2b Activity by CyP Inhibition Is Independent of the CsA-Calcineurin Complex
It has been traditionally assumed that CsA is a specific inhibitor of CaN 7, 26, 27 ; however, general inmunophilin inhibitors, such as CsA or FK506, are able to reduce CaN activity only after complexing with their CyP or inmunophilin target proteins, respectively. 7,26,27 Therefore, we needed to clarify whether CsA was affecting SERCA2b directly or through CaN. 28 To test this possibility, we used the specific CyP inhibitor, which does not show immunosuppressant properties or interfere with CaN activity, PKF-211-811-NX5, and the specific CaN inhibitor, cypermethrin. 29 As shown in Figure 5 , PKF-211-811-NX5 was able to modify Thr plus TBHQ-evoked Ca 2ϩ mobilization, poststimulus [Ca 2ϩ ] c , and Ca 2ϩ remaining in the stores. In contrast, cypermethrin was not able to reduce the amount of Ca 2ϩ sequestered by SERCA2b, thus suggesting that CaN is not involved in SERCA2b activity.
CyP A Complexes With SERCA2b and Regulates Its Function in Human Platelets
Human platelets express several types of CyPs, which have been shown to participate in platelet activation and platelet exocrine and paracrine functions. 30, 31 To identify possible CyPs involved in SERCA2b regulation, we incubated human platelets for 30 minutes at 37°C with several concentrations, 10 to 500 nmol/L, of sanglifehrin A, a CsA analogue that specifically targets CyP A. 32 As shown in Figure 6A, In addition, we investigated whether CyP A interacts with SERCA2b in human platelets by coimmunoprecipitation. Human platelets, in a Ca 2ϩ -free medium, were incubated for 5 minutes in the absence or presence of CsA, 50 mol/L, and then were stimulated for 1 minute either with Thr, 0.1 U/mL, or a combination of Thr plus TG and lysed. Samples were immunoprecipitated with anti-SERCA2 (IID8) antibody followed by Western blotting with an anti-CyP A antibody (anti-CyP A). In platelets, the anti-SERCA2 antibody recognizes SERCA2b, the only SERCA2 isoform identified. Our results revealed that CyP A associates with SERCA2b in resting cells ( Figure 6B ). This interaction was significantly decreased by 18% or 20% after treatment with Thr or Thr plus TG, respectively. The fact that no differences on CyP A/SERCA2b interaction are observed between samples treated with or without TG indicates that SERCA2b activity is not necessary for the association with CyP A. As shown in Figure 6B , the incubation of human platelets with CsA, Figure 6C ), which increases the coupling between both proteins in control (11.6Ϯ8.6%, nϭ4) or Thr-stimulated platelets (24.6Ϯ6.1%, PϽ0.05, nϭ4). These findings suggest that CyP A peptidylprolyl cis-transisomerase activity is required for its dissociation from SERCA2b induced by the physiological agonist Thr.
Finally, we investigated the role of stromal interaction molecule-1 (STIM1), which has been presented as the endoplasmic reticulum Ca 2ϩ sensor, in the regulation of SERCA2b. Coimmunoprecipitation experiments using 2 g/mL of anti-STIM1 antibody were performed to investigate the possible interaction between STIM1 and CyP A in resting platelets or platelets stimulated with Thr, 0.1 U/mL, alone or in combination with TG, 10 nmol/L, in the absence or presence of CsA. As shown in Figure 6D , our results revealed that CyP A associates with STIM1 in resting platelets, which is reduced by 39.1Ϯ10.9% after platelet stimulation with Thr (PϽ0.01, nϭ6) or by 45.7Ϯ8.5% in platelets stimulated with Thr plus TG (PϽ0.001, nϭ6). Treatment with CsA increased by 10.1Ϯ18.6% the coupling between STIM1 and CyP A in resting platelets (PϾ0.05, nϭ6). CsA was also able to enhance the STIM1-CyP A association by 32.7Ϯ10.9% in the presence of Thr (PϽ0.01, nϭ6) and by 28.6Ϯ6.7% in the presence of Thr plus TG (PϽ0.05, nϭ6).
Discussion
Recent studies [13] [14] [15] have reported that SERCA activity might be regulated by proteins targeted by CsA and other macrolide lactones, such as ivermectin or ascomicin, which mostly include several members of the immunophilin family. However, these studies [13] [14] [15] have reported contradictory results depending on the cell type investigated. We found that CsA, a CyP inhibitor, modifies Thr-evoked Ca 2ϩ mobilization without altering PMCA activity. This finding is different from previous results, but these discrepancies might be attributed to a different effect of CsA on distinct PMCA isoforms (PMCA1 and PMCA4), with PMCA4 being the isoform predominantly expressed in platelets, more likely insensitive to CsA. 17, 33, 34 To identify the SERCA isoform regulated by CsA, we stimulated platelets with Thr in the presence of specific inhibitors of the different SERCA isoforms in these cells (SERCA2b and SERCA3). 18 -21 When SERCA3 was inhibited by TBHQ, CsA was still able to alter Thr-induced Ca 2ϩ mobilization, including the ability of platelets to accumulate Ca 2ϩ into intracellular stores; however, when SERCA2b was inhibited by TG, CsA was unable to modify the Thr-evoked response, thus indicating that SERCA2b activity was inhibited in the presence of CsA. Meanwhile, SERCA3 activity seemed to be unaltered. SERCA2b inhibition, evoked by CsA, was confirmed by using cells electrotransjected with a specific anti-SERCA3 antibody. 22 Inhibition of SERCA1 isotype by CsA or ivermectin has been previously described by others 15 ; however, to our knowledge, this is the first time that a reduction of SERCA2b activity by CsA is reported, since previous studies reported that CsA either does not modify its activity 15 or even that CsA enhances SERCA2b activity. 16 A possible explanation for this controversy may be that previous studies did not consider the presence in their cell types of different rates of expression of SERCA isotypes, including SERCA2b or SERCA3, which has been documented in HUVEC-derived EA.hy926 cells, as a possible explanation for the different responses to histamine and its effects on SERCA activity. 35 In T-lymphocytes, addition of CsA, even at low concentrations, increased SERCA3a expression, while SERCA2b expression was diminished as observed by semiquantitative reverse transcriptase-PCR analysis. 36 In human platelets the rate of protein expression has been shown to be almost null due to the residual mRNA contents derived from their megakaryocyte precursors, so the effect of CsA on SERCA2b observed cannot be attributed to a change in protein expression.
In addition to CyPs, CsA has also been found to interact with CaN activity. 26 -28 In order to ascertain what protein was responsible for the effects of CsA we performed additional tests with the CaN inhibitor cypermethrin, a CsA-unrelated agent that targets CaN, 29 which failed to reproduce the effects of CsA, thus suggesting that CaN was not involved in the inhibition of SERCA2 activity induced by CsA. The effect of CsA was confirmed by using two nonimmunossupresant CsA-derivates, PKF-211-811-NX5 and sanglifehrin A, a specific inhibitor of CyP A. 32 These findings further demonstrate that the effect of CsA in SERCA2b is exclusive of CyPs, including CyP A, and it is not the result of an indirect effect of CsA over other proteins like CaN.
We have found interaction between Cyp A and SERCA2b and also between STIM1 and CyP A by coimmunoprecipitation in resting cells. These interactions are decreased during platelet stimulation with Thr, which actively depletes the Ca 2ϩ stores and initiates Ca 2ϩ reuptake mechanisms. Since SERCA2b activity is enhanced after Ca 2ϩ store depletion these findings suggest that CyP A might exert a negative role on SERCA2b so that disruption of the interaction between both proteins after Thr stimulation might be necessary for an increase in the activity of SERCA2b. The interaction between CyP A and SERCA2b was not affected by inhibition of SERCA2b by TG, which indicates that the activity of SERCA2b is not necessary for the formation of this protein complex. Similarly, STIM1/CyP A coupling found in resting platelets was reduced after intracellular Ca 2ϩ stores were depleted, which might indicate that STIM1 is also involved in the regulation of SERCA2b function. In contrast, the activity of CyP A is necessary for the dissociation from SERCA2b after Thr stimulation, as demonstrated by using CsA and sanglifehrin A, which reduced the ability of Thr to dissociate the SERCA2b/CyP A interaction.
In conclusion, here we described a new regulatory role of CyP A on SERCA2b activity mediated by protein-protein interaction and modulated by physiological agonists like Thr. [37] [38] This regulatory mechanism might be a possible target for preventing disorders evoked by Ca 2ϩ overload in human platelets 39 and other cells. 
